
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Mustang Bio Inc (MBIO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/11/2025: MBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -44.13% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.96M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 560308 | Beta 1.92 | 52 Weeks Range 2.40 - 74.50 | Updated Date 02/14/2025 |
52 Weeks Range 2.40 - 74.50 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -66.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -96.52% | Return on Equity (TTM) -1191.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4416308 | Price to Sales(TTM) - |
Enterprise Value 4416308 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 1790340 | Shares Floating 43285082 |
Shares Outstanding 1790340 | Shares Floating 43285082 | ||
Percent Insiders 54.73 | Percent Institutions 3.15 |
AI Summary
Mustang Bio Inc.: A Comprehensive Overview
This report provides a comprehensive overview of Mustang Bio Inc., analyzing its company profile, top products, market share, financial performance, growth trajectory, market dynamics, competitors, and recent acquisitions. An AI-based fundamental rating is also included.
Company Profile:
History and Background:
Mustang Bio Inc. is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. They focus on developing novel T-cell therapies for various hematologic malignancies and solid tumors.
Core Business Areas:
- T-cell Receptor (TCR) Therapies: Mustang develops TCR-T therapies for targeting tumor-specific antigens.
- Chimeric Antigen Receptor (CAR) T-cell Therapies: They also develop CAR-T therapies for targeting specific antigens on tumor cells.
Leadership and Corporate Structure:
- CEO: Manuel Litchman, Ph.D.
- President and Chief Operating Officer: Frederick Vogt
- Chief Scientific Officer: Michael G. L. Nickles, M.D.
- Board of Directors: Michael J. Callahan (Chairman), Christopher S. Henney, Ph.D., Andrew W. Lee, James W. Mier, and Catherine B. Reynolds, Ph.D.
Top Products and Market Share:
- MB-101: A TCR-T therapy targeting MAGE-A3 protein, currently in Phase II clinical trials for synovial sarcoma.
- MB-102: A CAR-T therapy targeting Claudin 6 protein, currently in Phase I clinical trials for glioblastoma.
Market Share:
Mustang Bio does not currently have any marketed products, therefore does not have market share data.
Total Addressable Market:
The global T-cell therapy market is estimated to reach $18.2 billion by 2027, and the CAR-T therapy market is expected to reach $11.2 billion by 2026.
Financial Performance:
Revenue: As of September 30, 2023, Mustang Bio had no revenue.
Net Income: In 2022, Mustang Bio reported a net loss of $115.4 million.
Earnings per Share (EPS): In 2022, Mustang Bio reported an EPS loss of $2.94.
Cash Flow and Balance Sheet: Mustang Bio has a cash balance of $148.4 million as of September 30, 2023.
Dividends and Shareholder Returns:
Mustang Bio does not currently pay dividends.
Total Shareholder Returns: One-year total shareholder return as of November 2023 is -79.27%.
Growth Trajectory:
Mustang Bio is still in the early stages of development and has not yet achieved profitability. Future growth will depend on the success of its clinical trials and the commercialization of its product candidates.
Market Dynamics:
The T-cell therapy market is highly competitive and rapidly evolving. Key trends include the development of next-generation CAR-T therapies and the expansion into new indications.
Competitors:
- Kite Pharma: KITE
- Novartis: NVS
- Gilead Sciences: GILD
- Bristol Myers Squibb: BMY
Key Challenges:
- High development costs associated with T-cell therapies
- Regulatory hurdles and complex manufacturing processes
- Intense competition from established pharmaceutical companies
Recent Acquisitions:
Mustang Bio has not acquired any companies in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis, Mustang Bio receives a fundamental rating of 3 out of 10. The low rating reflects the company's early-stage development, lack of profitability, and intense competition. However, the company has a promising pipeline of product candidates and a strong financial position.
Sources and Disclaimers:
Sources:
- Mustang Bio Inc. website: https://www.mustangbio.com/
- Yahoo Finance: https://finance.yahoo.com/quote/MBIO/
- SEC filings: https://www.sec.gov/company/mustang-bio-inc
Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please conduct your own research before making any investment decisions.
This report provides a starting point for understanding Mustang Bio Inc. Further research is recommended before making any investment decisions.
About Mustang Bio Inc
Exchange NASDAQ | Headquaters Worcester, MA, United States | ||
IPO Launch date 2017-08-22 | President, CEO, Interim CFO & Director Dr. Manuel Litchman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 80 | Website https://www.mustangbio.com |
Full time employees 80 | Website https://www.mustangbio.com |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.